Martine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of United Therapeutics stock in a transaction dated Friday, January 13th. The stock was sold at an average price of $261.52, for a total value of $2,092,160.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $33,997.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

United Therapeutics Trading Up 0.2 %

United Therapeutics stock opened at $260.02 on Friday. The business has a 50-day simple moving average of $270.72 and a two-hundred day simple moving average of $241.05. The company has a market cap of $11.85 billion, a P/E ratio of 17.69, a P/E/G ratio of 1.54 and a beta of 0.62. United Therapeutics Co. has a 52-week low of $158.38 and a 52-week high of $283.09. The company has a quick ratio of 9.39, a current ratio of 9.68 and a debt-to-equity ratio of 0.18.

United Therapeutics (NASDAQ:UTHR – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.57 by $1.34. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. The business had revenue of $516.00 million during the quarter, compared to the consensus estimate of $492.92 million. Analysts predict that United Therapeutics Co. will post 16.63 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Charter Oak Capital Management LLC purchased a new position in shares of United Therapeutics during the 2nd quarter valued at about $25,000. Cullen Frost Bankers Inc. purchased a new position in shares of United Therapeutics during the 2nd quarter valued at about $26,000. Guardian Wealth Advisors LLC purchased a new position in shares of United Therapeutics during the 3rd quarter valued at about $27,000. Hallmark Capital Management Inc. purchased a new position in shares of United Therapeutics during the 2nd quarter valued at about $33,000. Finally, Ronald Blue Trust Inc. purchased a new position in shares of United Therapeutics during the 2nd quarter valued at about $28,000. 95.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent analyst reports. Wedbush lifted their price target on United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. Oppenheimer lifted their price objective on United Therapeutics from $325.00 to $375.00 and gave the stock an “outperform” rating in a report on Thursday, November 3rd. JPMorgan Chase & Co. lifted their price objective on United Therapeutics from $240.00 to $265.00 and gave the stock an “overweight” rating in a report on Thursday, November 3rd. UBS Group assumed coverage on United Therapeutics in a report on Tuesday, December 6th. They issued a “buy” rating and a $320.00 price objective for the company. Finally, The Goldman Sachs Group assumed coverage on United Therapeutics in a report on Monday, December 5th. They issued a “sell” rating and a $230.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $283.64.

About United Therapeutics

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.